Akeso Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Akeso Inc (9926)
Akeso Inc stock price live, this page displays HK 9926 stock exchange data. View the 9926 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Akeso Inc real time stock price chart below.
What Is the Akeso Inc Stock Price Today?
The Akeso Inc stock price today is 94.80.
What Is the Stock Symbol for Akeso Inc?
The stock symbol for Akeso Inc is "9926."
What Stock Exchange Does Akeso Inc Trade On?
Akeso Inc is listed and trades on the Hong Kong stock exchange.
Is Akeso Inc a Good Stock to Buy?
Determining whether Akeso Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9926 quote. (ISIN: KYG0146B1032)
What Is the Akeso Inc Stock Price Today?
The Akeso Inc stock price today is 94.80.
What Is the Stock Symbol for Akeso Inc?
The stock symbol for Akeso Inc is "9926."
What Stock Exchange Does Akeso Inc Trade On?
Akeso Inc is listed and trades on the Hong Kong stock exchange.
Is Akeso Inc a Good Stock to Buy?
Determining whether Akeso Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9926 quote. (ISIN: KYG0146B1032)
94.80
+6.75(+7.67%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
93.05
96.95
52 wk Range
80.20
179.00
9926 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
93.0596.95
52 wk Range
80.20179.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
9926 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
169.60
Upside
+78.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Akeso Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Akeso Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Akeso Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Akeso Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Akeso Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
22 Buy
2 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 169.60
(+78.91% Upside)
Earnings
Latest Release
Mar 26, 2026
EPS / Forecast
-0.60 / --
Revenue / Forecast
1.64B / --
Compare 9926 to Peers and Sector
Metrics to compare | 9926 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9926PeersSector | |
|---|---|---|---|---|
P/E Ratio | −63.1x | −12.1x | −0.4x | |
PEG Ratio | 0.65 | 0.05 | 0.00 | |
Price/Book | 7.8x | 5.3x | 2.6x | |
Price / LTM Sales | 23.0x | 11.5x | 3.0x | |
Upside (Analyst Target) | 82.7% | 49.2% | 51.3% | |
Fair Value Upside | Unlock | −4.0% | 7.3% | Unlock |
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People’s Republic of China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Akeso (9926) Stock Price Today?
The Akeso stock price today is 94.80 HKD.
What Stock Exchange Does Akeso Trade On?
Akeso is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Akeso?
The stock symbol for Akeso is "9926."
What Is the Akeso Market Cap?
As of today, Akeso market cap is 81.11B HKD.
What Is Akeso's Earnings Per Share (TTM)?
The Akeso EPS (TTM) is -1.23.
From a Technical Analysis Perspective, Is 9926 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Akeso Stock Split?
Akeso has split 0 times.
How Many Employees Does Akeso Have?
Akeso has 3761 employees.
What is the current trading status of Akeso (9926)?
As of Jul 02, 2026, Akeso (9926) is trading at a price of 94.80 HKD, with a previous close of 88.05 HKD. The stock has fluctuated within a day range of 93.05 HKD to 96.95 HKD, while its 52-week range spans from 80.20 HKD to 179.00 HKD.
What Is Akeso (9926) Price Target According to Analysts?
The average 12-month price target for Akeso is 169.60 HKD, with a high estimate of 225.59602266 HKD and a low estimate of 120.50641693 HKD. 22 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +78.91% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.